Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 1999

View Archived Issues

Sepracor's progress in third quarter

Italian laboratory designs new phototherapeutic/photodiagnostic compounds

Antisense oligonucleotides that modulate human HER-2 expression patented

Rhone-Poulenc and Hoechst present new Aventis logo

Second-generation virus from Calydon begins clinical testing in prostate cancer

Coactinon effective and safe as part of first-line protease inhibitor-sparing regimen

Tenofovir disoproxil fumarate: clinical activity correlated with intracellular levels

PDE4-inhbitory pyridines disclosed by Janssen

Warner-Lambert patents new anticoagulants with quinolinone structure

Improved muscarinic agents for cognitive disorders

HMR's newest antiresorptive compounds

Schering-Plough files for marketing clearance for desloratadine on two continents

Protein Design Labs and Roche expand Zenapax partnership

StessGen begins trial of HspE7 for anal dysplasia

Alza and Crescendo report efficacy data for once-daily ADD/ADHD therapy

Pivotal data presented for Celgene's ADD/ADHD therapy

Cubist receives further grant funding for antiinfective research

Antihypertensive agent unexpectedly found to hold potential as male contraceptive

News from ASRM/CFAS '99: Hughes Institute hones in on anti-HIV spermicides

Dramatic results described for STI-571 in CML patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...